PRLD logo

Prelude Therapeutics Incorporated


PRLD: Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.


Show PRLD Financials

Consumer Interest
SEC Filings

Recent trades of PRLD by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by PRLD's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

Quiver Logo

No new patents for this ticker

U.S. Patents Dashboard
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of PRLD in WallStreetBets Daily Discussion


Recent insights relating to PRLD

CNBC Recommendations

Recent picks made for PRLD stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in PRLD

Corporate Flights

Flights by private jets registered to PRLD